Please login to the form below
cost
This page shows the latest cost news and features for those working in and with pharma, biotech and healthcare.
Entering the era of digital trials
Non- enrolling sites add to costs and trial durations. The problems continue once patients are enrolled. ... Attracted by the potential to speed enrolment and slash costs, Genentech, Novartis, Pfizer and other leading drugmakers have adopted virtual and
Latest news
-
Brexit to blame as firm plans to leave UK for Ireland
CEO Walt Rosebrough announced the news yesterday on an investor call, and said that remaining headquartered in the UK could cost the company $50m. ... It says the decision won’t materially change the day-to-day operations of its business, but estimated
-
MPs threaten to publish Vertex’s Orkambi price if no deal struck
Vertex has been attempting to gain reimbursement for its combination treatment Orkambi since 2016, but saw the drug rejected by cost effectiveness watchdog NICE that year. ... of the clinical and cost effectiveness of the drugs presented to the NICE
-
AbbVie sues NHS England over hep C procurement
At the time, it was reported that the aim was to drive the cost of treating HCV down to around £10, 000 from £35, 000 in return for initial three year
-
Orchard surpasses IPO expectations, raising $200m
In having acquired Strimvelis from GSK, Orchard leapfrogs many other gene therapy companies by gaining an established product - and one that is even recommended by England's hard-to-please cost
-
Medical cannabis now available on prescription, for some
authorised as being a cost-effective use of NHS resources by the National Institute for Health and Care Excellence (NICE).
More from news
Approximately 10 fully matching, plus 1,211 partially matching documents found.
Latest Intelligence
-
Brexit: can pharma ‘take back control’ of the narrative?
These business continuity plans come at an addition to the usual cost of doing business in the UK, therefore damaging the attractiveness of the market. ... All of these issues are made worse by the uncertainty caused by Brexit and the increasing cost
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
These costs will be tempered by discounts in both markets, and by a money back guarantee in the US if patients fail to respond, but still a very high price which ... Onpattro got its first European launch in Germany in early October, where the drug’s
-
Lonely planet: why there is dwindling value in pharma travelling alone
The cost of healthcare is soaring as populations age, with the growing burden of disease placing intolerable pressure on global health systems and economies.
-
The NHS in 2022: how pharma can contribute to new models of care
That would probably include providing specialist expertise in a disease area, and articulating the true cost and impact of a disease and treatment through real world evidence (RWE). ... Training, education and communications. Applying industry rigour and
-
AstraZeneca: building a new ‘open innovation’ pharma company
The cost of the project has also risen sharply from an original estimate of £330m to £500m, with the pharma company dropping original construction firm Skanska, and hiring Mace to finish
More from intelligence
Approximately 2 fully matching, plus 405 partially matching documents found.
Latest appointments
-
Merck appoints new chief information officer
He has a proven track record in successfully managing large-scale IT transformation initiatives, as well as building cost-effective international IT organisations.”.
-
Baird Capital backs Prescient Healthcare Group
decisions. “The market for the company’s services is set to continue to grow strongly as biopharmaceutical companies seek to develop and market products in a cost- and time-effective way.
-
Peter Kelly named managing director of Accord Healthcare UK
We remain committed to R&D and bringing cost competitive new products to market at the earliest opportunity.
-
IFPMA appoints Fumie Griego as assistant director general
and background in global affairs, including intellectual property protection, pricing, costs, value issues and health diplomacy.
-
Sandoz UK promotes Tim de Gavre to country head
As a market, the UK has one of the highest levels of generic use of any global market, and the NHS is also under severe cost pressures. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs,
More from appointments
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest from PMHub
-
Make your pharma exhibition stand paperless
Stuff simply gets lost or left in hotel rooms. And when you consider the cost of copy, design and full-colour printing, this can be a painful pill to swallow.
-
Three key development areas in the management of multiple sclerosis
Research presented at ECTRIMS shows promise for NfL as a simple biomarker of MS activity and severity that could provide a cost-effective option to support MRI.
-
Adult and Pediatric Hemoconcentrators Market Investment Research Report 2015 - 2025
The hemocor HPH hemoconcentrator provides lower cost method of processing hemodiluted blood. ... Request to Sample of Report @ . Globally, increasing number of patients with cardiac diseases, demand for cost effective method of processing hemodiluted
-
Spinal Fusion Market Set to Grow Exponentially During the Forecast, 2025
such as reimbursement cuts and heavy government regulations, high surgery cost, risk factors involved in the surgery etc. ... fusion holding the fact that increased number of technological advancements have made the devices and surgeries cost-effective.
-
Future and Scope of Diabetic Shoes Market by 2026
Besides this, medically prescribed diabetic footwear can also decreases the high cost of care related with diabetic foot ulcers and amputations. ... Comfort and others. The manufacturers are focusing on production of low cost diabetic shoes especially in
More from PMHub
Approximately 3 fully matching, plus 412 partially matching documents found.
Featured jobs
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Senior Account Executive, London, Medical Communications
-
Excellent package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Senior Account Manager
-
Negotiable
-
Associate Medical Director
-
Highly Competitive
-
Senior Medical Writer
-
Competitive Salary
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
-
New Business Director - PR
-
Competitive Salary and benefits
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Account Director
-
Excellent benefits
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
-
Account Director
-
£48, 000 - £60, 000
-
Medical/ Scientific Director
-
Salary TBC
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Associate Director
-
£75, 000-90, 000
-
Medical Writers
-
Competitive Salary and Benefits
- Director, Market Access / HEOR - North-West
-
Negotiable
-
Consumer Health Account Director
-
Circa £60, 000 Gym and More
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
Subscribe to our email news alerts
- Cranial Closure And Fixation Devices Market to Reflect Steady Growth Rate by 2026
- Brain Cancer Diagnostics Market Investment Research Report 2016-2026
- Healthcare sector bullish despite political uncertainty
- Bioprocessing Analytics Equipment Market is anticipated to register a CAGR of 4.5% over the forecast period 2028
- Behavioural Health Market is expected to expand at 3.4% CAGR over the forecast period 2018-2028.
- Prurigo Nodularis Treatment Market is poised to expand at 3.4% CAGR over the forecast period of 2018–2028
PMHub
Cogora
Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...
Latest intelligence
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
- Nudge-nudge, think-think
- Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
- Quality in Care Diabetes 2018: the best in innovative diabetes care
- Awards highlight new evidence-based approaches to improving care...
Quick links
Infographics
